|Bid||216.00 x 0|
|Ask||222.00 x 0|
|Day's Range||203.98 - 223.00|
|52 Week Range||5.50 - 231.21|
|Beta (5Y Monthly)||-2.93|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
If you want to know who really controls Synairgen plc (LON:SNG), then you'll have to look at the makeup of its share...
Synairgen's (LSE: SNG) stock skyrocketed on Monday amid news that the largely unknown British respiratory therapeutics company had demonstrated in a phase 2 clinical trial that its inhalable drug SNG001 reduced the chances of coronavirus patients needing a ventilator by a stunning 79%. While the results are still preliminary and need robust third-party confirmation, investors are already curious about whether SNG001 poses a threat to established competitors in the coronavirus therapeutics space, like Gilead Sciences (NASDAQ: GILD) and its antiviral drug remdesivir. In a nutshell, there's a lot to be hopeful about when it comes to Synairgen's new therapy, but that doesn't mean you should rush to sell your Gilead shares.
AstraZeneca and Oxford University's COVID-19 vaccine showed positive results in early stages of human trials. Yahoo Finance's Anjalee Khemlani joins the On the Move panel to discuss.